2 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona
3 New Drugs Direct Renin Inhibitors Endothelin Antagonists
4 DRI Works at the Point of Activation of the RAAS
5 Aliskiren Reduced PRA Alone and in Combination With Ramipril*
6 Aliskiren Maintained 80% SBP Reduction 4 Days After Last Dose
7 Why Use a DRI? Aliskiren and Aliskiren + HCTZ Have an Established d Safety and Tolerability Profile
8 Endothelin Antagonists Endothelin (ET) antagonists such as bosentan have been used successfully to treat pulmonary hypertension. Trials with multiple ET antagonists are under way in hypertension and CHF. The selective ET A antagonist, darusentan, may be approved by the FDA in 2009.
11 New Approaches Emphasis on Cost:Benefit Emphasis on Systolic Blood Pressure Combination Therapy Emphasis on Endpoints
12 Emphasis on Cost:Benefit Many generic antihypertensive agents are now available for as little as $10/90 days. A 4 drug antihypertensive regimen utilizing diuretics, Beta blockers, ACE-Is and CCBs can be used at a cost of $162.22/year or $0.44/day
13 Prevalence of Hypertension Increases With Age
14 Isolated Systolic Hypertension Accounts for Most Uncontrolled HTN N in the Elderly
15 Relative Importance of DBP and SBP as Predictors of CHD as a Function of Age
16 Systolic vs Diastolic BP as Predictors of Outcomes in ASCOT-BPLA MI + CHD Death + Revascularization HR/1 SD P SBP 1.16 <.0001 Fatal + Nonfatal Stroke HR/1 SD P SBP 1.38 <.0001 DBP DBP PP 1.23 <.0001 PP 1.45 <.0001
17 Combination Antihypertensive Therapy Evolution and Rationale
19 BP Control Usually Requires Combination Therapy
20 JNC VII The initiation of therapy with more than one drug increases the likelihood of achieving BP goal in a more timely fashion. The use of fixed-dose combinations may be more convenient and simplify the treatment regimen, and may cost less than the individual components prescribed separately.
21 JNC VII The use of multidrug combinations often produces greater BP reduction at lower doses of the component agents, resulting in fewer side effects. However, caution is advised in initiating therapy with multiple agents, particularly in some older persons and in those at risk for orthostatic hypotension, such as diabetics with autonomic dysfunction.
22 Combination Antihypertensive Therapy: Potential Reductions in Dose-Related Side Effects Thiazide diuretics with potassium-sparing diuretics May reduce K+ loss and decrease the risk of hypokalemia Thiazide diuretics with ARBs or ACE inhibitors May reduce risk of hypokalemia ACE inhibitors and dihydropyridine CCBs Combinations may have less edema than seen with dihydropyridines alone Beta-adrenoreceptor-blockers and direct vasodilators or dihydropyridine CCBs Beta-blockers reduce tachycardia seen with these agents Epstein, et al. Arch Intern Med. 1996;156: Jeunemaitre, et al. Am J Cardiol. 1988; 62: Pedrinelli, et al. Hypertension. 2000; 35: Van Zwieten. Clin Investig. 1992;70(suppl 1):
23 Guideline Recommendations Regarding Initial Use of Combination TherapyT
24 Increased Persistence* with Single-pill Combination (SPC) vs Separate Pill Therapy
25 Single Pill Combination Therapy Demonstrates Improved Compliance in Hypertensive Patients Risk ratio (95% CI) % Weight Taylor et al 0.74 (0.67, 0.81) 27.1 Dezii 0.74 (0.65, 0.84) 13.9 NDC dataset 0.81 (0.77, 0.86) 46.4 Dezii 0.71 (0.62, 0.80) 12.6 Overall (95% CI) 0.77 (0.73, 0.80) P< Risk Ratio Favors FDC Agent Retrospective Study FDC fixed dose combination Bangalore S, Am J Med 2007;120: Favors Individual Agents Given Separately
26 Potential Benefits of Single-Pill Combinations
27 Emphasis on Endpoints New Lessons from Clinical Trials Does which drugs we use matter? In moderate risk patients? In high risk patients? In very high risk patients?
28 ALLHAT Does the First Drug Matter? Moderate Risk Diuretic vs ACE-I vs CCB
29 ALLHAT Design: Double-blind, randomized, prospective Patients: 42,418, mean age 67, with HTN +1 other risk factor, controlled on no more than 2 drugs, partially treated BP 156/89 Intervention: Chlorthalidone mg vs amlodipine mg vs lisinopril mg vs doxazosin 1-8 mg Primary Endpoint: MI or CHD death
30 ALLHAT Mean Systolic and Diastolic Blood Pressure During Follow-up Chlorthalidone Chlorthalidone Systolic BP (mmhg) Amlodipine Lisinopril Compared to chlorthalidone: SBP significantly higher in amlodipine (~1 mmhg) and lisinopril (~2 mmhg) groups. Diastolic BP (mmhg) Amlodipine Lisinopril Compared to chlorthalidone: DBP significantly lower in amlodipine group (~1 mmhg) Follow-up, yrs SBP=systolic blood pressure DBP=diastolic blood pressure ALLHAT Research Group. JAMA. 2002;288: org Copyright 2002, American Medical Association.
31 Cumulative Fatal CHD and Nonfatal MI event rate (%) No. at Risk Chlorthalidone Amlodipine Lisinopril ALLHAT Primary Outcome by Treatment Group Time to event, yrs Chlorthalidone Amlodipine Lisinopril ALLHAT Research Group. JAMA. 2002;288: Copyright 2002, American Medical Association org
32 ALLHAT Conclusions The doxazosin arm was stopped early for higher CHF rates. The Primary Combined Endpoint of MI + CHD Death was not different with chlorthalidone, amlodipine or lisinopril. BP was lower in the chlorthalidone group as were CVA, angina and revascularization. The long term significance of more new onset diabetes in the chlorthalidone group is unclear.
33 OnTarget Design: Double-blind, randomized, prospective Patients: 25,620 with vascular disease or DM with TOD, treated BP at baseline 142/82 Intervention: ramipril 10 mg vs telmisartan 80 mg vs the combination Primary Endpoint: MI, CVA, CV death or CHF hospitalization
34 Kaplan-Meier Curves for the Primary Outcome in the Three Study Groups The ONTARGET Investigators. N Engl J Med 2008;358:
35 Relative Risks in Prespecified Subgroups The ONTARGET Investigators. N Engl J Med 2008;358:
36 Discontinuation of Study Medications and Selected Reasons for Permanent Discontinuation The ONTARGET Investigators. N Engl J Med 2008;358:
37 OnTarget Conclusions The Primary Composite Endpoint of MI, CVA, CV Death or CHF hospitalization did not differ between ramipril, telmisartan or the combination. Telmisartan was better tolerated than ramipril and both were better tolerated than the combination. For cardioprotection in patients with vascular disease or diabetes, telmisartan is equal to ramipril and the combination of ACEI and ARB has no advantage and is less well tolerated.
38 LIFE Design: Double-blind, randomized, prospective Patients: 9,193 with HTN and LVH, mean age 67, untreated BP at baseline 174/98 Intervention: losartan mg vs atenolol mg Primary Endpoint: MI, CVA or death
39 LIFE Study Blood Pressure During Follow-up Systolic mmhg Losartan Atenolol Mean Arterial Diastolic Study Month Dahlof B, et al. Lancet. 2002;359: Reprinted with permission from Elsevier Science. org
40 Proportion of patients with first event (%) LIFE Study Primary Composite Endpoint Intention-to-treat Adjusted risk reduction 13 0%, P=0 021 Unadjusted risk reduction 14 6%, P=0 009 Atenolol Losartan Study Month Losartan (n) Atenolol (n) Dahlof B, et al. Lancet. 2002;359: Reprinted with permission from Elsevier Science. org
41 Proportion of patients with first event (%) LIFE Study Fatal and Non-Fatal Stroke Intention-to-treat Adjusted risk reduction 24 9%, P=0 001 Unadjusted risk reduction 25 8%, P= Atenolol Losartan Study Month Dahlof B, et al. Lancet. 2002;359: Reprinted with permission from Elsevier Science. org
42 LIFE Diabetes and ISH Does the First Drug Matter? Very High Risk ARB vs Beta Blocker
43 Proportion of patients with first event(%) LIFE Study Diabetes Subgroup Total Mortality Adjusted risk reduction 38 7%, P=0 002 Unadjusted risk reduction 40 1%, P=0 001 Atenolol Losartan Study Month Lindholm LH, et al. Lancet. 2002;359: Reprinted with permission from Elsevier Science. org
44 LIFE: Total Mortality Diabetes Subgroup 24 Proportion of patients (%) L H Lindholm et al. Lancet 2002;359: Atenolol Losartan 4 Adjusted Risk Reduction 38.7%, p=0 002 Unadjusted Risk Reduction 40.1%, p= Study Month
45 Endpoint rate (%) LIFE Study ISH Subgroup Total Mortality Unadjusted relative risk reduction=30%; P=0.03 Adjusted relative risk reduction=28%; P=0.046 Atenolol Losartan Study month Kjeldsen SE, et al. JAMA. 2002;228: Copyright 2002, American Medical Association. org
46 LIFE Conclusions The Primary Combined Endpoint of MI, CVA or Death, but particularly CVA, were lower with losartan than with atenolol. In the Very High Risk, Diabetes and ISH subgroups, even Total Mortality was lower with losartan. In High Risk patients with hypertension, initial therapy with ARB is superior to Beta Blocker.
47 ASCOT-BPLA Do the First and Second Drug Matter? High Risk CCB + ACEI vs Beta Blocker + diuretic
48 ASCOT-BPLA Design: Double-blind, randomized, prospective Patients: 19,257, mean age 63, with HTN + 3 other risk factors, untreated BP 165/95 Intervention: amlodipine 5-10 mg + perindopril 4-8 mg vs atenolol mg + bendroflumethiazide mg Primary Endpoint: MI (clinical or silent) or CHD death
49 ASCOT BPLA Primary Endpoint Risk Reduction Percent Non-fatal MI, fatal CHD Atenolol ± thiazide (474 events) Amlodipine ± perindopril (429 events) 1.0 HR=0.90 (95% CI, ) P= Years Number at risk Amlodipine ± perindopril Atenolol ± thiazide Dahlöf B et al. Lancet. 2005;366:
50 ASCOT BPLA Secondary Endpoints Unadjusted Hazard Ratio (95% CI) Endpoint (n amlo vs aten) Non-fatal MI* +fatal CHD (390 vs 444) Total coronary endpoint (753 vs 852) Total CV event and procedures(1362 vs 1602) All-cause mortality (738 vs 820) Cardiovascular mortality (263 vs 342) Fatal and non-fatal stroke (327 vs 422) Fatal and non-fatal heart failure (124 vs 159) P Value P = P = P < P = P = P = P = Favors amlodipine ± perindopril Favors atenolol ± thiazide The area of each square is proportional to the amount of statistical information. *Excludes silent non-fatal MI. Adapted from Dahlöf B et al. Lancet. 2005;366:
51 ASCOT-BPLA Conclusions The Primary Combined Endpoint of MI or CHD Death and most secondary endpoints, including total mortality, were lower in the amlodipineperindopril (CCB-ACEI) than in the atenololthiazide group. BP was lower in the CCB-ACEI group, but the Hazard Ratios for the Primary Endpoint and CVA were still significant when adjusted for BP. The CCB-ACEI regimen was superior to the Beta Blocker-Thiazide regimen.
52 ACCOMPLISH Does the Second Drug Matter? High Risk ACEI + CCB vs diuretic
53 ACCOMPLISH Design: Double-blind, randomized, prospective Patients: 11,506, mean age 68, with HTN and vascular disease or DM or LVH or CKD, Treated BP with a mean of 2 drugs 145/80 Intervention: benazepril mg + amlodipine 5-10 mg vs hydrochlorothiazide mg Primary Endpoint: MI, CVA, CHF, coronary intervention, resuscitated SCD or CVD death
54 160 ACCOMPLISH Blood Pressure Results Benazepril/amlodipine Benazepril/HCTZ 140 mmhg Patients, n Months Benazepril/amlodipine (N) 5,740 5,517 5,404 5,178 5,010 4,866 4,298 2,804 1,074 Benazepril/HCTZ (N) 5,757 5,537 5,408 5,222 5,033 4,825 4,299 2,529 1,042 The mean SBP/DBP following titration was 131.6/73.3 mm Hg in the benazepril/amlodipine group and 132.5/74.4 mm Hg in the benazepril/hctz group. The mean difference in SBP/DBP between the 2 groups was 0.9/1.1 mmhg (p<0.001) Jamerson K, et al. N Engl J Med. In Press
55 0.16 ACCOMPLISH Primary Endpoint Benazepril/amlodipine (552 patients with events: 9.6%) Benazepril/HCTZ (679 patients with events: 11.8%) 20% Cumulative event rate HR 0.80 (95%CI ); p< ,096 1,277 Time to first CV mortality/morbidity (days) Months Patients at risk (N) Benazepril/amlodipine 5,512 5,317 5,141 4,959 4,739 2,826 1,447 Benazepril/HCTZ 5,483 5,274 5,082 4,892 4,655 2,749 1,390 Jamerson K, et al. N Engl J Med. In Press
56 ACCOMPLISH Components of the Primary Endpoint* HR (95%CI) p-value Composite CV mortality/morbidity 0.80 ( ) <0.001 CV mortality 0.80 ( ) 0.08 MI (fatal/non-fatal) 0.78 ( ) 0.04 Stroke (fatal/non-fatal) 0.84 ( ) 0.17 Hospitalisation for unstable angina 0.75 ( ) 0.14 Coronary revascularisation procedure 0.86 ( ) 0.04 *Only the first event in an individual patient was counted in the analysis of the primary end point Jamerson K, et al. N Engl J Med. In Press Favours Benazepril /amlodipine Favours Benazepril /HCTZ
57 ACCOMPLISH Subgroup analyses for the primary endpoint Subgroups Benazepril/ amlodipine N=5744 Benazepril /HCTZ N=5762 Hazard Ratio (95% CI) p-value n(%) n(%) Sex Male 365 (10.6) 461 (13.1) 0.80 ( ) Female 187 (8.1) 218 (9.7) 0.83 ( ) 0.06 Age 65 years 70 years 386 (10.1) 260 (11.0) 474 (12.4) 323 (13.8) 0.81 ( ) 0.79 ( ) Diabetes Yes 307 (8.8) 383 (11.0) 0.79 ( ) No 245 (10.8) 296 (12.9) 0.82 ( ) 0.02
58 ACCOMPLISH Conclusions In the total cohort, as well as the 6,946 patients with diabetes, the Primary Combined Endpoint (-20%), as well as MI (-20%) and coronary revascularization (-14%), were lower in the benazeprilamlodipine than in the benazeprilhydrochlorothiazide group. When added to initial therapy with ACEI, CCB is superior to thiazide diuretic.
59 Summary: New Drugs The first Direct Renin Inhibitor, aliskiren, is effective and very well tolerated. The place of Direct Renin Inhibition in the antihypertensive armamentarium is as yet undetermined. The first selective antagonist of the endothelin A receptor, darusentan, may be approved this year for treatment of hypertension. The place of Selective Endothelin Receptor Antagonism in the antihypertensive armamentarium is as yet undetermined.
60 Summary: New Goals The goal BP for patients with low risk, uncomplicated hypertension remains unchanged at <140/90. The goal BP for patients with Diabetes, CKD, Angina or high risk of CAD is <130/80. The goal BP for patients with Diabetes + CKD is <120/70. In 2010, JNC VIII may revise these goals.
61 Summary: New Approaches I Nearly all patients with hypertension can be treated for less than $0.45 per day. Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy. The ALLHAT authors. Adopted in JNC VII. Based upon current costs and subsequent clinical trials, this conclusion is no longer valid.
62 Summary: New Approaches II After age 55, Systolic BP is a strong predictor of CV events and Diastolic BP becomes a negative predictor. Initial treatment with combination therapy is reasonable and appropriate for patients with BP >20/10 mmhg above goal BP. Single Pill combination therapy has several advantages over Separate Pill therapy, especially better compliance.
63 Summary:Emphasis on Endpoints While BP reduction is of primary importance in treating hypertension, choice of agent is important in High Risk Patients. With different agents, at the same reduction in BP, there may be differences in MI, CVA, other CV endpoints, Total Mortality and new onset Diabetes. Multiple clinical trials support the superiority of ACE-Is, ARBs and CCBs over Beta Blockers and thiazide diuretics.
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr
Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
Hypertension Guidelines 2016 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative
SIIIA UNIVERSITA degli STUDI di TORINO FACOLTA DI MEDICINA E CHIRURGIA DIPARTIMENTO DI MEDICINA ED ONCOLOGIA SPERIMENTALE SCU MEDICINA INTERNA CENTRO IPERTENSIONE ARTERIOSA AOU S.GIOVANNI BATTISTA TORINO
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
Choice of therapy in esse... http://www.uptodate.co... Page 1 of 28 Official reprint from UpToDate www.uptodate.com Print Back Choice of therapy in essential hypertension: Recommendations Authors Norman
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
Amlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management Bum-Kee Hong Yongdong Severance Hospital Yonsei University College of Medicine Rationale for Multiple-Mechanism Therapy Inadequacy
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
1 U.S. Department of Health and Human Services The Hypertension, Detection, and Follow-up Program (HDFP) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) National
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension
This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,
EVIDENCE-BASED CLINICAL MEDICINE Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection? Hean Teik Ong, FRCP, FACC, FESC Purpose:
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
ORIGINAL CONTRIBUTION JAMA-EXPRESS Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
h i g h b l o o d p r e s s u r e where are we at? The recent literature has raised doubts about the role of ßblockers for lowering blood pressure and the New Zealand Guidelines Group is updating the Assessment
JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Blood Pressure Management Wein T, Gladstone D (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2017 Heart and Stroke Foundation September
2012. 4. 20-21 춘계심장학회 _ 부산 Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia? Jeong Bae Park, MD, PhD Cardiology, Cheil General Hospital, Kwandong University, Seoul, Korea The Pulse : revived
Implementation: Joint National Committee on High Blood Pressure JNC 8 Joel Handler, MD Kaiser Permanente Care Management Institute Hypertension Lead Southern California Permanente Group Objective & Outline
UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 firstname.lastname@example.org Global Mortality 2000: Impact
Isolated Systolic Hypertension in the elderly Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg Case no 1 Man aged 75, from Kosovo, in CH since 1.5 years Former smoker (45 PY) BP:
Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension
Challenges in Hypertension: Incorporating Evolving Clinical Data Into Practice Faculty Jan Basile, MD Professor of Medicine Seinsheimer Cardiovascular Health Program Division of General Internal Medicine
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
HYPERTENSION UPDATE: NEW JNC 8 Guideline vs OLD Federal Motor Carrier Safety Regulations PLEASE STAND BY WEBINAR WILL BEGIN AT 12:00 PM PST FOR AUDIO: CALL 866-740-1260 / ACCESS CODE: 764-4915# Conflict
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
Review Advances in CKD 216 Published online: January 15, 216 Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Hillel Sternlicht George L. Bakris Department of Medicine, Section
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
Getting Hypertension Under Control Learning Objectives EXPLAIN the factors involved in patient medication non-adherence. OUTLINE the results of studies focusing on medication adherence issues in patients
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Fixed-dose Combination Therapy in Hypertension: Focus on Fixed-dose
Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of
Research Original Investigation A Systematic Review and Meta-analysis Connor A. Emdin, HBSc; Kazem Rahimi, DM, MSc; Bruce Neal, PhD; Thomas Callender, MBChB; Vlado Perkovic, PhD; Anushka Patel, PhD IMPORTANCE
Retour sur le congrès de l AHA 2017 Paul Poirier MD, PhD, FRCPC, FACC, FAHA, FCCS Professeur Faculté de pharmacie Université Laval Responsable du programme de prévention/réadaptation cardiaque Canagliflozin
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
Creative blood pressure management: whys and the tricks Cynthia D. Caraballo-Hunt, MD Kaiser/OHSU Family Medicine Faculty Beaverton Medical Office NW Permanente, Portland, OR Objectives 1. Describe current
Drug Class Review on Calcium Channel Blockers FINAL REPORT September 2003 TABLE OF CONTENTS Introduction 5 Scope and Key Questions 6 Methods 6 Literature Search 6 Study Selection 6 Data Abstraction 7 Validity
Controlling high blood pressure prevents disease Recognition and Management of Acute Hypertensive Emergencies David idweiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Functional Genomics
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia Percieved risk Actual risk Sehestedt et al,
Update in Outpatient Medicine JNC 8, Hypertension and More March 6 th 2015 Robert Gluckman, MD, FACP CMO Providence Health Plans Disclosures Stock Holdings Abbott Labs Abbvie Bristol Myers Squibb GE Proctor
ESC CONGRESS HIGHLIGHTS PREVENTION Pr Michel KOMAJDA Dept of Cardiology University Pierre & Marie Curie Pitie Salpétrière Hospital PARIS France Thank you to B Williams and S Sharma email@example.com
SPECIAL REPORT ALLHAT and its implications in the diabetic population Samy I McFarlane, MD, MPH, FACP Associate Professor of Medicine, Fellowship Program Director, Division of Endocrinology, Diabetes and
Emerging Challenges in Primary Care: 2017 Hypertension 2017: The Times and Guidelines Are Changing 1 Faculty Jan Basile, MD Professor of Medicine Seinsheimer Cardiovascular Health Program Division of General
Blood Pressure Control in the Elderly How High Should You Go? Sara Linedecker, PharmD PGY-2 Ambulatory Care Resident University of Texas at Austin College of Pharmacy Blackstock Family Practice/CommUnityCare
Guide to the New Hypertension Guidelines LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital Disclosures None Objectives Describe the new hypertension staging and blood pressure goals and
Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression
nature publishing group STATE OF THE ART Management of Blood Pressure in Patients With Diabetes Ehud Grossman 1 and Franz H. Messerli 2 Hypertension is a major modifiable risk factor for cardiovascular